Medicines for Addiction
Adial is a clinical-stage biopharmaceutical company focused on the treatment and prevention of addictions and other unmet medical needs.
RECENT NEWS
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
GLEN ALLEN, Va., May 15, 2025 — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2025. Cary Claiborne, CEO of Adial […]
HEAR FROM OUR EXPERTS
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar.
Key Opinion Leader Webinar
Managing Through Mixed Trial Results And An Economic Downturn
Ben Comer
Chief Editor, Life Science Leader
November 1, 2022
What would Jack Welch do? Cary Claiborne knows the answer from nearly 15 years working at GE and GE Capital, during a time that overlapped closely with Welch’s tenure as CEO. In August, Claiborne himself became CEO of Adial Pharma, a Charlottesville, VA-based biopharmaceutical company with a novel approach to treating alcohol use disorder (AUD). Claiborne faces several distinct challenges: mixed topline results from a Phase 3 trial of lead candidate AD04, the potential need to fund and conduct another trial prior to seeking regulatory approval, and managing the company through a difficult economic downturn. Lessons learned during formative work experiences at GE, the first place Claiborne worked after graduating from Rutgers University in 1982, have followed him through executive-level financial roles in industries including telecoms, retail, energy, renewable fuels, and biopharmaceuticals.
Spotlight Series
Stay updated with insights from Adial’s executives on the latest company news and key developments in addiction research.
View All Spotlight Series
Strategic Growth & Innovation: Tony Goodman on Adial’s Vision for Precision Medicine
04/03/2025
Adial’s approach with AD04 integrates a genetic focus, specifically targeting certain genotypes. How has this personalized medicine approach been received within the addiction treatment community?
read more →AD04
Our lead investigational drug candidate, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated for the potential treatment of AUD in patients with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test.
Learn More